Teva Branded Pharmaceutical Products R&D
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Teva Branded Pharmaceutical Products R&D sits in the top decile of US sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count).
Teva Branded Pharmaceutical Products R&D: 167 sponsored US clinical trials, 6 recruiting.
Teva Branded Pharmaceutical Products R&D sponsors 167 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 131 completed. 89 of these trials are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Asthma, with 13 trials.
Top-decile sponsor footprint
Teva Branded Pharmaceutical Products R&D ranks in the top decile of sponsors by registered trial count (#177 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
131 of 159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
167 total, page 2 of 4
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
NCT02621931
Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
NCT02638103
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
NCT02513160
An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
NCT02501629
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
NCT02452190
Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following Bunionectomy
NCT02487108
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
NCT02499900
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
NCT02190721
Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older
NCT02437604
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
NCT02410356
Study of TV-1106 in Growth Hormone-Deficient Adults
NCT02410343
An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients
NCT02315144
Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017
NCT02315131
A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)
NCT02365636
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
NCT02284568
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
NCT02215616
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
NCT02078960
Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers
NCT02215941
Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma
NCT02175771
Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
NCT02184767
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
NCT02141854
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
NCT02139644
A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics
NCT02126839
A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee
NCT02068599
A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women
NCT02092571
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
NCT02025556
Assessment of LBR-101 In Chronic Migraine
NCT02021773
A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
NCT02040779
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
NCT02031640
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma
NCT02040766
A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults
NCT02030457
Safety and Bioavailability of IV and SC LBR-101
NCT01991509
First Time Use of SD-809 in Huntington Disease
NCT01795859
Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets
NCT01922739
Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients
NCT01899144
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
NCT01922752
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
NCT01879748
Safety and Tolerability of Glatiramer Acetate
NCT01874145
Absolute Bioavailability of Reslizumab in Healthy Subjects
NCT01990443
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
NCT01887366
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
NCT01857323
Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma
NCT01844401
Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
NCT01811576
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain
NCT01789970
Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)
NCT01791972
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01707992
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects
NCT01772368
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)
NCT01783548
A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet
NCT01769677
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics
NCT01747629
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 37 |
| Phase 3 | 79 |
| Phase 4 | 10 |
Therapeutic Areas
What is open in the Teva Branded Pharmaceutical Products R&D pipeline
6 recruiting of 167 indexed (4% open); 131 completed (78%).
Phase mix: 89 late (III/IV) vs 74 early (I/II) (balanced across stages).
Top condition: Asthma (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Teva Branded Pharmaceutical Products R&D: open-pipeline peers nationwide
Peers matched on 167 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Teva Branded Pharmaceutical Products R&D sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 167 trials (± recruiting share)
- Wyeth is now a wholly owned subsidiary of Pfizer · 167 trials · 0% recruiting
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
- Bayer · 4% recruiting · 591 trials
Related
What to do with this Teva Branded Pharmaceutical Products R&D page
167 registered trials is a research-attention snapshot, not an endorsement of Teva Branded Pharmaceutical Products R&D or any single study.
- 6 of Teva Branded Pharmaceutical Products R&D's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Asthma is the condition Teva Branded Pharmaceutical Products R&D studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Asthma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Teva Branded Pharmaceutical Products R&D pipeline card: 167 registered trials from official public datasets.Report a data error.